Global Liver Disease Cases Surge, Projected to Hit 1.8 Billion by 2050
A Lancet study reveals that Metabolic dysfunction-associated steatotic liver disease (MASLD) affected 1.3 billion people globally in 2023, a 143% increase since 1990. Projections indicate this number could rise to 1.8 billion by 2050, primarily driven by population growth, obesity, and high blood sugar levels. The study emphasizes the need for urgent global health prioritization and preventive measures.
Key Highlights
- MASLD cases reached 1.3 billion in 2023, a 143% surge since 1990.
- Projections estimate 1.8 billion MASLD cases globally by 2050.
- Rising obesity and high blood sugar are key drivers of MASLD.
- North Africa and the Middle East show disproportionately higher MASLD rates.
- Global health action and preventive measures are urgently needed.
- India faces a significant burden, with 35-40% of adults affected by fatty liver.
A significant global health concern has emerged with a recent study published in The Lancet Gastroenterology & Hepatology, indicating that Metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly known as non-alcoholic fatty liver disease (NAFLD) — affected an estimated 1.3 billion people worldwide in 2023. This figure represents a staggering 143% increase since 1990, underscoring the rapidly escalating burden of liver disease globally. The study, which utilized data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, projects an alarming rise to approximately 1.8 billion cases by the year 2050. This projected increase is primarily attributed to two major factors: global population growth and widespread lifestyle changes, including escalating rates of obesity and high blood sugar levels. The research highlights that high blood sugar levels are the leading driver of MASLD-related health problems globally, followed closely by high Body Mass Index (BMI) and smoking, emphasizing the strong links between MASLD, type 2 diabetes, and obesity. Regions such as North Africa and the Middle East are reported to have disproportionately higher rates of MASLD compared to other regions, indicating significant regional disparities in the disease's prevalence. The study also noted that while the age-standardized prevalence rate of MASLD increased by 28.6% from 1990 to 2023, the crude number of cases saw a substantial rise of 142.7%. The global prevalence rate in 2023 was estimated at 14,429.3 per 100,000 population, a 29% increase from 1990. The researchers observed that MASLD was more common in men than women, with the highest prevalence rates in older adults (80-84 years), but a larger absolute number of affected individuals were younger, particularly those aged 35-39 for men and 55-59 for women. Globally, liver disease accounts for approximately 2 million deaths annually, making it responsible for about 4% of all deaths worldwide. The majority of these liver-related deaths, about two-thirds, occur in men, primarily due to complications of cirrhosis and hepatocellular carcinoma. In India, the situation is particularly concerning. Various studies suggest that 35-40% of the Indian adult population is affected by fatty liver disease, a figure considered a conservative estimate. Alarmingly, approximately 35% of Indian children also have fatty liver disease. When combining adult and child populations, it's estimated that 40-50 crore people in India are currently affected by fatty liver. Recent research also indicates that about 40% of Indians who do not consume alcohol are affected by non-alcoholic fatty liver disease (NAFLD), with at least 2.4% experiencing liver fibrosis. Major metropolitan cities in India, such as Delhi, Bengaluru, Pune, Hyderabad, and Chennai, report high prevalence rates between 37% and 42%. The study in The Lancet Gastroenterology & Hepatology emphasizes that MASLD should be recognized as a global health priority, necessitating comprehensive policy responses, widespread awareness campaigns, and targeted interventions. The researchers stressed the critical need to address the rising cases by focusing on the prevention of obesity, high blood sugar, and other lifestyle-related risks. The study also points out that MASLD is not currently included in the UN's Sustainable Development Goals or WHO's primary noncommunicable disease action plans, highlighting a policy gap that needs urgent attention. The convergence of factors like increasing urbanization, sedentary lifestyles, consumption of processed foods and sugary diets, and stress are identified as key drivers of this epidemic, particularly in fast-paced urban environments. Prevention strategies for liver disease include moderating alcohol consumption, maintaining a healthy weight, eating a balanced diet, regular exercise, avoiding risky behaviors like sharing needles, getting vaccinated against hepatitis A and B, and being cautious with medications and herbal supplements. The study serves as a critical wake-up call, underscoring the immense and growing threat posed by liver disease and the imperative for immediate global action to mitigate its impact.
Frequently Asked Questions
What is Metabolic dysfunction-associated steatotic liver disease (MASLD)?
MASLD, formerly known as non-alcoholic fatty liver disease (NAFLD), is a condition where excess fat accumulates in the liver, not caused by heavy alcohol use. It is associated with metabolic risk factors such as obesity, high blood sugar, and high blood pressure.
What are the main drivers behind the projected increase in liver disease cases?
The primary drivers identified for the projected increase in MASLD cases are global population growth and significant lifestyle changes, including rising rates of obesity and high blood sugar levels worldwide.
Which regions are most affected by MASLD?
The study indicates that regions such as North Africa and the Middle East have disproportionately higher rates of MASLD compared to other parts of the world.
What are the key recommendations for preventing liver disease?
Prevention strategies include maintaining a healthy weight, adopting a balanced diet, regular physical activity, moderating alcohol consumption, avoiding risky behaviors, getting vaccinated against hepatitis, and being cautious with medications and toxins.
What is the estimated prevalence of fatty liver disease in India?
In India, it is estimated that 35-40% of the adult population is affected by fatty liver disease, with around 35% of children also affected. In major metropolitan cities, the prevalence can be as high as 37-42%.